Compugen (CGEN) vs Compass Therapeutics (CMPX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Compugen (CGEN) has outperformed Compass Therapeutics (CMPX) over the past year, gaining 22.2% versus a loss of 71.7%. Over five years, CGEN leads with a -66.2% price change compared with -68.2% for CMPX. Compugen is the larger company by market cap ($203.7 million vs $183.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEN | CMPX |
|---|---|---|
| Share price | $2.15 | $1.02 |
| Market cap | $203.66M | $183.69M |
| 1-day change | -3.15% | +2.19% |
| YTD return | +40.52% | -81.01% |
| 1-year return | +22.16% | -71.75% |
| 5-year return | -66.19% | -68.22% |
| P/E ratio (TTM) | 5.66 | — |
| EPS (TTM) | $0.38 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.24 | $6.88 |
| 52-week low | $1.43 | $0.829 |
| Distance from 52-week high | -33.64% | -85.17% |
| Average volume | 247.77K | 4.08M |
| Shares outstanding | 94.72M | 180.09M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEN has outperformed CMPX by 93.9 percentage points over the past year.
CGEN vs CMPX FAQ
Which is bigger, Compugen or Compass Therapeutics?
Compugen (CGEN) is larger, with a market capitalization of $203.66M compared with $183.69M for Compass Therapeutics (CMPX).
Which stock has performed better over the past year, CGEN or CMPX?
CGEN returned +22.16% over the past 12 months, compared with -71.75% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compugen and Compass Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.